CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome
Article in Frontiers in Pharmacology (February 2024)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in murine model of the SARS-CoV-2-related acute respiratory distress syndrome
Preprint in bioRxiv (November 2023)
Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study
Article in Frontiers in Medicine (November 2023)